Summary
This content was automatically synthesized by Credo's AI models directly from the original source text.
AI summaries can make mistakes — double-check important details against the original source.
1 Sample Definition And Size
Healthy adult men and women (N = 30; 15 in AG1® group, 15 in placebo group) participated in a 4‑week randomized, double‑blind, placebo‑controlled parallel clinical trial ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39352252/?utm_source=openai)).
2 Study Type
Randomized, double‑blind, placebo‑controlled clinical trial with parallel design over four weeks ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39352252/?utm_source=openai)).
3 Conflicts Of Interest
T.N.Z. declared no direct conflict. J.R.T. and T.N.Z. received funding from dietary supplement companies, honoraria for speaking, and consulting fees. T.O.K. and J.R.T. are employees of Athletic Greens International. Remaining authors declared no commercial or financial relationships. Funders had no role in data collection, analysis, or interpretation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39352252/?utm_source=openai)).
4 Results Summary
AG1® supplementation enriched probiotic taxa Lactobacillus acidophilus, Bifidobacterium bifidum, L. lactis CH_LC01, and Acetatifactor sp900066565 ASM1486575v1, and reduced Clostridium sp000435835. Functionally, AG1® enriched two pathways and diminished none, whereas placebo enriched six and diminished five. Digestive Quality of Life Questionnaire (DQLQ) showed a trend toward improvement in AG1® group (+62.5%, p = 0.058, Cohen’s d = 0.73) versus a reduction (−50%) in placebo. No significant changes in bowel frequency, stool consistency, or clinical safety markers (CBC, CMP, lipid panel, hemodynamics) were observed. Only one mild adverse event (bloating) in AG1® group and one moderate event (abdominal pain and diarrhea) in placebo group ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39352252/?utm_source=openai)).